Chargement en cours...
Folate-Conjugated Rapamycin Slows Progression of Polycystic Kidney Disease
Activation of the mammalian target of rapamycin (mTOR) signaling pathway is aberrant in autosomal-dominant polycystic kidney disease (ADPKD). The mTOR inhibitors, such as rapamycin, ameliorate PKD in rodent models, but clinical trials have not shown benefit, possibly as a result of low tissue concen...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Nephrology
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3458469/ https://ncbi.nlm.nih.gov/pubmed/22859856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2012040367 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|